AVISCERA BIOSCIENCE  
AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 

Sclerostin (SOST) ELISA Kit

A New Biomarker for Metabolic Syndrome

SCLEROSTIN: ANOTHER VASCULAR CALCIFICATION INHIBITOR?

Context:Sclerostin, a Wnt antagonist, produced by osteocytes regulates osteoblast activity and is a well-established key player in bone turnover. Recent data indicate that the Wnt pathway may also be involved in vascular calcification.Objective:The present study tests the hypothesis that serum sclerostin levels are associated with vascular calcification in patients with chronic kidney disease (CKD) not yet on dialysis.Design, setting, participants and measurements:We performed a cross-sectional analysis in 154 CKD patients. Aortic calcification (AC) was assessed by lumbar X-ray and scored with a maximum score of 24. In addition to traditional and non-traditional cardiovascular risk factors, serum sclerostin levels were assessed (ELISA). Regression analysis was performed to identify determinants of serum sclerostin and AC.Results:AC was present in 59% of patients. Higher age (p <0.0001), male gender (p= 0.006), lower eGFR (p=0.0008), lower bone specific alkaline phosphatase (p= 0.03) and the absence of AC (p=0.006) were identified as independent determinants of higher serum sclerostin levels. In univariate logistic regression, higher age, diabetes, cardiovascular history, higher BMI, higher serum CRP and sclerostin levels and lower eGFR were all associated with the presence of AC. In multivariate analysis, lower, not higher, sclerostin levels (p=0.04; OR per ng/ml 0.24), higher age (p<0.0001, OR per year 1.17) and cardiovascular history (p=0.02, OR for a positive cardiovascular history 3.83) were identified as independent determinants of AC.Conclusions:In this cohort of CKD patients we found that patients with aortic calcifications had higher sclerostin levels. However, in multivariate analysis the association became inverse. Additional clinical and experimental studies are urgently required to clarify whether or not sclerostin protects against progression of vascular calcification.
Claes KJ, et al. J Clin Endocrinol Metab. 2013 Jun 20. [Epub ahead of print]

Atherosclerotic Disease in Type 2 Diabetes Is Associated With an Increase of Sclerostin Levels

OBJECTIVEWnt/β-catenin signaling is related to the pathogenesis of several diseases. Sclerostin is an inhibitor of Wnt/β-catenin signaling. However, there are few data regarding the sclerostin levels and vascular disease. Our aim was to examine the relationship between serum sclerostin and atherosclerotic disease (AD) in type 2 diabetes mellitus (T2DM).RESEARCH DESIGN AND METHODSWe performed a cross-sectional study including 78 T2DM patients (45.3% females, mean age 59 ± 5.7 years; 54.7% males, 57.4 ± 6.7 years).RESULTSSerum sclerostin concentrations of T2DM patients in the AD group were significantly higher than in the non-AD group (P = 0.006). For each increase of 1 pmol/L in sclerostin level, there was a 4% increase of the risk of AD in T2DM patients. A concentration of ≥42.3 pmol/L showed a sensitivity of 69% and a specificity of 54.8% to detect an increased risk of AD. In males, sclerostin levels were higher in those with AD (P = 0.04), abnormal intima-media thickness (IMT) (P = 0.004), carotid plaques (P < 0.001), and aortic calcification (P < 0.001). In females, higher levels of sclerostin were related to abnormal IMT (P = 0.03) and aortic calcifications (P = 0.004). Homocysteine (β = 0.319 [95% CI 0.561-2.586], P = 0.003) and IMT (β = 0.330 [14.237-67.693], P = 0.003) were positive correlated with sclerostin.CONCLUSIONSCirculating sclerostin is increased in T2DM patients with atherosclerotic lesions. Although the sample size of our study was small, these data suggest that sclerostin levels could be a major modulator of Wnt signaling in AD with implications in T2DM patients.
Morales-Santana S, et al. Diabetes Care. 2013 Jan 8. [Epub ahead of print]
Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus
Context: Diabetes mellitus is a risk factor for osteoporotic fractures. Sclerostin is an inhibitor of bone formation. However, there are no data about sclerostin levels in type 2 diabetes mellitus (T2DM).
Objectives: The aims were to evaluate serum sclerostin in T2DM patients and to analyze its relationship with bone metabolism.
Design, Setting and Patients: This was a cross-sectional study. We compared serum sclerostin in the T2DM group (n = 74) and control group (n = 50), and we analyzed its relationship with calciotropic hormones, bone turnover markers, bone mineral density (BMD), and morphometric vertebral fractures.
Results: Sclerostin levels were significantly higher in T2DM patients than control subjects (P < 0.001) and in T2DM males than in T2DM females (P < 0.001). Serum sclerostin was positively correlated with age in males T2DM (P = 0.031). In linear regression analysis, gender, study group, and age were predictive of sclerostin levels (P < 0.05). Sclerostin concentrations were positively associated with duration of T2DM (P = 0.064) and glycated hemoglobin (P = 0.074) independently of age in T2DM patients. Sclerostin was inversely related to bone turnover markers (P < 0.05) and positively related to lumbar spine, femoral neck, and total hip BMD (P< 0.05) in the T2DM group. Sclerostin was significantly lower in osteoporotic than nonosteoporotic patients with T2DM (P = 0.048).
Conclusions: Circulating sclerostin is increased in T2DM independently of gender and age. Serum sclerostin is also correlated with duration of T2DM, glycated hemoglobin, bone turnover markers, and BMD in T2DM patients. Additional studies are needed to evaluate the role of sclerostin on bone metabolism in this population.
García-Martín A, et al. J Clin Endocrinol Metab. 2012 Jan;97(1):234-41. doi: 10.1210/jc.2011-2186. Epub 2011 Oct 26.

Association of circulating sclerostin levels with fat mass and metabolic disease--related markers in Japanese postmenopausal women

Context: Wnt/-catenin signaling is related to the pathogenesis of osteoporosis, diabetes, and metabolic diseases. Sclerostin is an inhibitor of Wnt/-catenin signaling. However, there are few data regarding the relationship between sclerostin levels and metabolic disease.
Objectives: This study aimed to identify the relationship between serum sclerostin levels, body composition markers, and the markers of metabolic disease.
Design, Setting and Patients: The present study is a cross-sectional study. We measured serum sclerostin levels in 352 Japanese postmenopausal women and analyzed the relationship of these levels with bone mineral density, abdominal fat mass, and biochemical markers. The mean (sd) age of the subjects was 65.5 (9.3) yr.
Results: Serum sclerostin levels were positively correlated with percentages of abdominal and gynoid fat. We also analyzed the association between serum sclerostin levels and biochemical markers related to metabolic diseases. Multivariate analysis revealed that the serum sclerostin levels were significantly correlated with the levels of low-density lipoprotein cholesterol and homocysteine.
Conclusions: The circulating sclerostin levels were associated with fat mass. The circulating sclerostin levels were also correlated with low-density lipoprotein cholesterol and homocysteine.
Urano T, Shiraki M, Ouchi Y, Inoue S. J Clin Endocrinol Metab. 2012 Aug;97(8):E1473-7. doi: 10.1210/jc.2012-1218. Epub 2012 May 25.
Human Soluble Sclerostin (SOST)ELISA Kit
Code No.: SK00385-01
Size: 96 T
Price: $360.00 USD
Standard Range:62.5-4000 pg/mL
Sample Type: cell cultures, serum, plasma
Sample require: 200 uL
Intra-CV: 4-8%
Inter-CV: 6-10
Protocol: PDF
Name
Code No.
Size
Price ($)
Soluble Sclerostin (SOST) (Human) ELISA Kit
96 T
360.00